Treatment Information

Back

Bladder Cancer treatment details. Biologic therapy.

Fox Chase Cancer Center, Philadelphia, PA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Philadelphia, PA
Treatments:Biologic therapyHospital:Fox Chase Cancer Center
Drugs:Journal:Link
Date:Oct 2012

Description:

Patients:
This phase 2 study involved pretreated metastatic urothelial cancer patients who were divided into two separate treatment groups. There were 11 patients in group A with a median age of 70 years and 9 were male. Group B had 28 patients with a median age of 69 years and 21 males.

Treatment:
Patients in group A were treated with the biologic therapy agent cetuximab, which is a monoclonal antibody that inhibits the EGFR protein and interferes with cancer cell growth.

Patients in group B were treated with cetuximab and the chemotherapy agent paclitaxel.

Toxicities:
The most severe toxicities in group A were of grade 3 and included rash and pruritus (skin toxicity/itching).

There were treatment-related deaths due to unspecified causes in group B. Grade 3-5 rash, fatigue, pain, and infection were reported.

Results:
The median overall survival for group A and group B was 3.9 and 9.7 months, respectively.

Support:
This study was partially supported by Bristol-Myers Sqibb.

Correspondence: Dr. Yu-Ning Wong; email: [email protected]



Back